Prevalance and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC)
dc.authorid | 0000-0002-4075-6692 | en_US |
dc.contributor.author | Kunter, E. | |
dc.contributor.author | Çermik, H. | |
dc.contributor.author | Işıtmangil, T. | |
dc.contributor.author | Kandemir, E. G. | |
dc.contributor.author | Yaylacı, Mustafa | |
dc.contributor.author | Öztürk, A. | |
dc.date.accessioned | 2024-07-12T21:10:22Z | |
dc.date.available | 2024-07-12T21:10:22Z | |
dc.date.issued | 2003 | en_US |
dc.department | Fakülteler, Tıp Fakültesi | en_US |
dc.description.abstract | The c-erbB2 oncoprotein is highly expressed in approximately one third of non-small cell lung cancer (NSCLC) patients. We determined the status of c-erbB2 expression in our patients with NSCLC and investigated its correlation with disease stage, histological type and response to treatment. Eighty-four patients were examined for the expression of c-erbB2 by immunohistochemistry using a polyclonal antibody. The scoring criteria of Clinical Trial Assay (CTA) were used to evaluate staining (0 to +3). c-erbB2 overexpression was determined in 35% of the cases. Tumors from higher stage disease (stage IIIb-IV) were more often c-erbB2 positive in adenocarcinoma (ADC) (p=0.04). In addition, there was an association between c-erbB2 score and disease stage in ADC patients (p=0.03). Our study did not demonstrate an association of c-erbB2 overexpression with response to chemotherapy. We conclude that c-erbB2 overexpression may be a prognostic marker for evaluating tumor progression in NSCLC patients but further studies must be performed with larger patient populations. | en_US |
dc.identifier.citation | Türken O, Kunter E, Çermik H, Işıtmangil T, Kandemir EG, Yaylacı M, Öztürk A. Prevalance and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma, AEPress. 50, s. 257-261. | en_US |
dc.identifier.endpage | 261 | en_US |
dc.identifier.issn | 0028-2685 | |
dc.identifier.issn | 1338-4317 | |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 257 | en_US |
dc.identifier.uri | http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=675&category_id=31&option=com_virtuemart&vmcchk=1&Itemid=1 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12415/4242 | |
dc.identifier.volume | 50 | en_US |
dc.institutionauthor | Türken, Orhan | |
dc.language.iso | en | en_US |
dc.publisher | AEPress | en_US |
dc.relation.ispartof | Neoplasma | en_US |
dc.relation.publicationcategory | Uluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanı | en_US |
dc.rights | CC0 1.0 Universal | * |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.snmz | KY03086 | |
dc.subject | Non-small | en_US |
dc.subject | lung | en_US |
dc.subject | cancer | en_US |
dc.subject | c-erbB2 | en_US |
dc.title | Prevalance and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC) | en_US |
dc.type | Article | |
dspace.entity.type | Publication |